Cargando…

Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease

Three types of new coronaviruses (CoVs) have been identified recently as the causative viruses for the severe pneumonia-like respiratory illnesses, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and corona-virus disease 2019 (COVID-19). Neither therapeutic agents...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akaji, Kenichi, Konno, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504761/ https://www.ncbi.nlm.nih.gov/pubmed/32867349 http://dx.doi.org/10.3390/molecules25173920

Ejemplares similares

Design and synthesis of a series of serine derivatives as small molecule inhibitors of the SARS coronavirus 3CL protease
por: Konno, Hiroyuki, et al.
Publicado: (2016)

Synthesis and evaluation of phenylisoserine derivatives for the SARS-CoV 3CL protease inhibitor
por: Konno, Hiroyuki, et al.
Publicado: (2017)

Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant
por: Akaji, Kenichi, et al.
Publicado: (2008)

Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor
por: Yoshizawa, Shin-ichiro, et al.
Publicado: (2020)

Evaluation of a non-prime site substituent and warheads combined with a decahydroisoquinolin scaffold as a SARS 3CL protease inhibitor
por: Ohnishi, Kouji, et al.
Publicado: (2019)

Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: Structure–activity relationship study
por: Thanigaimalai, Pillaiyar, et al.
Publicado: (2013)

Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: Design, synthesis, biological evaluation, and docking studies
por: Thanigaimalai, Pillaiyar, et al.
Publicado: (2013)

Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety
por: Konno, Sho, et al.
Publicado: (2013)

Fused-ring structure of decahydroisoquinolin as a novel scaffold for SARS 3CL protease inhibitors
por: Shimamoto, Yasuhiro, et al.
Publicado: (2015)

Proteases of SARS Coronaviruses
por: Mukherjee, Rukmini, et al.
Publicado: (2023)

Practical synthesis of peptide C-terminal aldehyde on a solid support
por: Konno, Hiroyuki, et al.
Publicado: (2013)

Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents
por: Kuo, Chih-Jung, et al.
Publicado: (2008)

Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity
por: Du, Lanying, et al.
Publicado: (2007)

Molecular docking based design of Inhibitors for viral Non-Nucleosidase as potential anti-retroviral agents
por: Alharbi, Ahmed, et al.
Publicado: (2020)

Allosteric Binding Sites of the SARS-CoV-2 Main Protease: Potential Targets for Broad-Spectrum Anti-Coronavirus Agents
por: Alzyoud, Lara, et al.
Publicado: (2022)

Possible SARS-coronavirus 2 inhibitor revealed by simulated molecular docking to viral main protease and host toll-like receptor
por: Hu, Xiaopeng, et al.
Publicado: (2020)

The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds
por: Báez-Santos, Yahira M., et al.
Publicado: (2015)

Quaternary Structure of the SARS Coronavirus Main Protease
por: Chang, Gu-Gang
Publicado: (2009)

Viral Proteases as Targets for Coronavirus Disease 2019 Drug Development
por: Zhu, Wei, et al.
Publicado: (2021)

Repurposing of known anti-virals as potential inhibitors for SARS-CoV-2 main protease using molecular docking analysis
por: Hakmi, Mohammed, et al.
Publicado: (2020)

The Effects of Side-Chain Configurations of a Retro–Inverso-Type Inhibitor on the Human T-Cell Leukemia Virus (HTLV)-1 Protease
por: Awahara, Chiyuki, et al.
Publicado: (2022)

The Molecular Mechanism of Domain Swapping of the C-Terminal Domain of the SARS-Coronavirus Main Protease
por: Terse, Vishram L., et al.
Publicado: (2021)

Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design
por: Wang, Fenghua, et al.
Publicado: (2016)

The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate
por: Wang, Hao, et al.
Publicado: (2022)

Evaluation of acridinedione analogs as potential SARS-CoV-2 main protease inhibitors and their comparison with repurposed anti-viral drugs
por: Bhardwaj, Vijay Kumar, et al.
Publicado: (2021)

Protease-anti-protease compartmentalization in SARS-CoV-2 ARDS: Therapeutic implications
por: McElvaney, Oisin F., et al.
Publicado: (2022)

Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors
por: Chen, Li-Rung, et al.
Publicado: (2005)

Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors
por: Ramajayam, R., et al.
Publicado: (2010)

Synergistic Inhibitor Binding to the Papain‐Like Protease of Human SARS Coronavirus: Mechanistic and Inhibitor Design Implications
por: Lee, Hyun, et al.
Publicado: (2013)

Varying molecular interactions explain aspects of crowder-dependent enzyme function of a viral protease
por: Ostrowska, Natalia, et al.
Publicado: (2023)

Design and Evaluation of Bispidine-Based SARS-CoV-2 Main Protease Inhibitors
por: Shcherbakov, Dmitriy, et al.
Publicado: (2021)

Evolution of host protease interactions among SARS-CoV-2 variants of concern and related coronaviruses
por: Kastenhuber, Edward R., et al.
Publicado: (2022)

Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases
por: Yang, Haitao, et al.
Publicado: (2005)

Molecular cloning, expression, purification, and mass spectrometric characterization of 3C-like protease of SARS coronavirus
por: Sun, Haifang, et al.
Publicado: (2003)

Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus
por: Prashantha, C.N., et al.
Publicado: (2021)

Discovery of novel oxazole-based macrocycles as anti-coronaviral agents targeting SARS-CoV-2 main protease
por: Al-Wahaibi, Lamya H., et al.
Publicado: (2021)

Molecular targets for the rational design of drugs to inhibit SARS coronavirus
por: Brockway, Sarah M., et al.
Publicado: (2004)

Promising anti-SARS-CoV-2 drugs by effective dual targeting against the viral and host proteases
por: Elseginy, Samia A., et al.
Publicado: (2021)

Cell Type-Specific Anti-Viral Effects of Novel SARS-CoV-2 Main Protease Inhibitors
por: Geiger, Nina, et al.
Publicado: (2023)

Characterization of trans‐ and cis‐cleavage activity of the SARS coronavirus 3CL(pro) protease: basis for the in vitro screening of anti‐SARS drugs
por: Lin, Cheng-Wen, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_63o6ul8crcck9m8laec8ok3skd